Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- AstraZeneca Japan Settles All Labor Suits
June 4, 2018
- Meiji Seika Pharma Chief Sounds Negative about Authorized Generic Biz
June 4, 2018
- JCR to Launch Japan PIII for BBB-Penetrating Hunter Syndrome Drug
June 4, 2018
- FY2017 Earnings Roundup - 1: Major Japan Makers Braced for Gloomier Year Ahead at Home, See 4.4% Dip
June 4, 2018
- Japan Drug Makers See Rising Overseas Sales Ratio amid Uphill Battle at Home: Tally
June 1, 2018
- Daiichi Sankyo Kicks Off PII for DS-8201 in NSCLC
June 1, 2018
- Shionogi Grabs Rights to Hsiri’s Mycobacterial Disease Therapies
June 1, 2018
- Roxadustat Hits Primary Endpoint in Japan PIII: Astellas/FibroGen
June 1, 2018
- FDA Accepts Eisai’s Fycompa for Pediatric Indication Review
June 1, 2018
- Astellas Files Japan NDA for JAK Inhibitor Peficitinib in RA
June 1, 2018
- Kissei’s Spinocerebellar Ataxia Treatment Fails to Hit Primary Targets in Japan PIII Study
June 1, 2018
- 3 Japan Drug Makers Launch Industry-Academia Consortium on Drug Discovery for Immune-Mediated Inflammatory Diseases
June 1, 2018
- Takeda Licenses Relugolix to ASKA in Women’s Health Field
June 1, 2018
- Perspective on Takeda/Shire Deal - 3: Takeda Shareholders Got Short End of the Stick
May 31, 2018
- Japan’s 1st Enbrel Biosimilar Makes Its Debut
May 31, 2018
- FDA Action Date for Mogamulizumab Extended for 3 Months: Kyowa Kirin
May 31, 2018
- Kowa to Launch Parmodia after Skipping 3 Listing Rounds
May 30, 2018
- Astellas’s Gilteritinib Gets FDA Priority Status
May 30, 2018
- Perspective on Takeda/Shire Deal - 2: Acquisition Might Mint More Investment Opportunities, Positive or Negative Not Yet Clear
May 30, 2018
- Chugai Files Actemra for Cytokine Release Syndrome
May 30, 2018
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…